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ABSTRACT 
 
Heat related morbidities and mortalities are disproportionately high in the aged population 
(≥60 yr).  Aging without overt illness is associated with the attenuation of heat dissipation 
mechanisms including cutaneous vasodilation and eccrine sweating responses.  These age-
related decrements in thermoregulatory function are well represented in literature discussing 
heat dissipation, yet despite attempts to investigate a potential signaling mechanism 
between sweating and skin blood flow (SkBF), a functional link has not been 
demonstrated.  Recent evidence supports a role of nitric oxide (NO), a potent signaling 
molecule in cutaneous vasodilation, as additionally signaling the eccrine sweating 
response.  The aim of this study was to investigate the putative role of NO in eccrine sweat 
gland signaling in young and primary aged individuals.  Prior to experimentation, pilot 
studies were conducted to develop experimental drug dilutions to achieve a successful flow 
matching protocol.  In two subjects, three intradermal microdialysis (MD) probes were 
inserted into the left ventral forearm and perfused with 1) Lactated Ringer’s solution, 2) 
Epoprostenol sodium (EPO) + NG-Nitro-L-arginine (L-NNA), and 3) Sodium Nitroprusside 
(SNP) + L-NNA.   Regional sweating rates (RSR) over each MD membrane were measured 
using ventilated capsules with a laser Doppler probe housed in each capsule for 
measurement of red cell flux (laser Doppler flux, LDF) and divided by mean arterial blood 
pressure (Cutaneous vascular conductance (CVC) = LDF/MAP) as an index of 
SkBF.  Subjects completed a whole body heating protocol to a 1°C rise in sublingual 
temperature.  Maximal CVC values were obtained pharmacologically at the end of each 
protocols using 25 mM SNP. During whole body heating in the second pilot, the L-NNA/EPO 
site displayed lower levels of CVC than the control site, implying the EPO had become 
inactive.  A buffer solution was created to maintain EPO stability at physiological pH.  The 
next steps are to complete pilot tests with EPO in buffer to ensure it remains active and to 
achieve a successful flow matching protocol before beginning the sweating study.  
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BACKGROUND AND SIGNIFICANCE  
When exposed to thermal stress, the aged population (≥60 years of age) consistently exhibit 
the greatest vulnerability to heat related illnesses, with a reported 82-92% excess mortality 
occurring in this group.[1]  Human primary aging is associated with attenuation of heat 
dissipation mechanisms, including the ability to increase skin blood flow (SkBf) and eccrine 
sweating responses.[2]   Age-related thermoregulatory dysfunction has become of increasing 
relevance considering scientists predict a greater frequency and severity of heat waves 
which may exceed the physiological capacity of vulnerable groups.[1]   
The physiological responses to heat stress include a significant increase in cutaneous 
vasodilation (VD) and stimulation of eccrine sweating, with the latter serving as the most 
effective avenue of heat loss.[2]  Eccrine sweating becomes especially important when 
ambient air temperatures exceed skin temperature, due to convective heat loss via 
vasodilation being hindered.[3]  Despite extensive literature concerning the physiological 
mechanisms involved in heat dissipation, the exact mechanisms governing heat dissipation 
processes and the relationship between sweating and SkBF remain unclear.  It is 
speculated that a key active effector of cutaneous vasodilation, nitric oxide (NO) is also 
involved with signaling the eccrine sweat response.  Demonstrating a functional link 
between cutaneous vasodilation and the sweat response would provide novel information on 
the regulation of eccrine sweating and potentially provide knowledge supporting the creation 
of treatment measures to improve heat dissipation of older adults.   
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Human Thermoregulation 
Human thermoregulation is achieved via a balance of heat production and heat loss 
mechanisms.  Humans are homeotherms, regulating core temperature (Tcore)  independently 
of the environment at a set point of approximately 37°C.[4]    During temperate conditions, 
resting metabolic heat production is equalized predominately by dry heat exchange through 
means of conduction, convection, and radiation.[1]  Elevations in Tcore may occur during 
exercise or exposure to high ambient air temperatures, activating heat dissipation 
mechanisms including cutaneous vasodilation and eccrine sweating responses.  In 
response to heat stress, initially vasoconstrictor tone is withdrawn; after a certain threshold 
is reached active cutaneous vasodilation and eccrine sweating are stimulated.[4]   
Cutaneous vasodilation is achieved via increased cardiac output and redistribution of blood 
flow from renal and splanchnic vascular beds to vascular beds important in 
thermoregulation.[5]  This redistribution of blood to the cutaneous circulation facilitates 
convective heat transfer from the core to the periphery.  This thermoregulatory response 
provides dynamic results; modest changes in vasodilation produce profound increases in 
heat transfer. For example, SkBF may increase from a resting value of approximately 250 
mL/min up to 6 to 8 L/min during hyperthermia, representing nearly 60% of cardiac output.[4]     
Eccrine sweating serves as the most effective avenue of heat loss and is especially 
important for heat loss when ambient air temperature exceeds mean skin temperature 
(~34°C), rendering efforts of convective heat loss via vasodilation inefficient.[6] The exact 
mechanisms which govern the sweat response and cutaneous vasodilation remain elusive, 
although it is generally agreed that acetylcholine (ACh) is the primary signaling molecule for 
eccrine sweating while ACh and an unknown cotransmitter primarily induce cutaneous 
vasodilation.  It has been observed that these thermoregulatory responses become 
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attenuated with primary aging and additionally that the aged become increasingly dependent 
on NO to induce vasodilation, yet this system is also blunted with age.  Considering that 
eccrine sweating becomes especially important when ambient air temperatures exceed 
mean skin temperature and also that the attenuation of thermoregulation mechanisms is 
apparent with primary aging, investigation of age-related alterations in thermoregulation and 
the potential mechanistic relationship between skin blood flow and eccrine sweating has 
become an attractive area of study.   
Age-Related Alterations in Thermoregulation 
Aging in the absence of overt pathology is associated with attenuated reflex vasodilatory 
and sweating response during thermal stress.[5]  These alterations appear to be peripheral in 
origin, due to decreased sensitivity of the active vasodilator system.[5] These age-related 
decrements in vasodilation occur in the cutaneous microcirculation, resulting in a delay in 
cutaneous microvascular responses and subsequent blunted thermoregulatory function.   
Control of both reflex and local mechanisms of the cutaneous vasculature are altered with 
age.[2]  Minson et al. [7] compared cardiac output and renal and splanchnic blood flow in 
young (~23 years) and older (~70 years) subjects during passive whole body heating and 
found that the increase in cardiac output and reductions in visceral blood flow observed in 
young subjects was reduced with age. The reduced cardiac output observed in aged 
individuals was largely attributed to a lower stroke volume and at the lower cardiac output, 
and less blood was redistricted towards the skin for thermoregulation.[7]  Similarly, Johnson 
and colleagues [2] observed a 30% reduction in blood flow redistributed from visceral 
vascular beds to the cutaneous circulation in older individuals, reinforcing the significant 
decrements in their ability to dissipate heat. [2]  
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Holowatz and colleagues [8] have extensively studied the mechanisms involved in altered 
thermoregulatory control in aged skin.  They have observed that when the enzyme involved 
in NO production, nitric oxide synthase (NOS),  was inhibited, cutaneous vasodilation was 
reduced to a larger extent in aged skin compared to younger persons exposed to the same 
level of heat stress.[8]  It was also found that the contribution of cholinergic active 
vasodilation co-transmitters to reflex vasodilation is functionally absent in the aged 
population.[5]  Researchers have concluded that with advancing age, individuals become 
increasingly dependent on NO to vasodilate, yet the system in also blunted with age.[5]   
Holowatz et al.[8] additionally concluded that with advancing age, arginase activity, which 
competes for the NOS substrate, L-arginine, limits L-arginine availability necessary for NO 
production (See Figure 1. for signaling pathways).  The researchers additionally investigated 
whether cutaneous vasodilation alterations associated with age were related to increased 
oxidative stress.[8]  They observed that the antioxidant, ascorbate, augmented cutaneous 
vasodilation responses in aged subjects compared to levels of younger subjects.[8]  
However, ascorbate did not alter a response in young subjects, implying attenuated active 
vasodilation functioning with advanced age is in part due to an age associated increase in 
oxidative stress.[8]  
When considered alongside the right shift in the Tcore threshold for vasodilation and 
sweating, older individuals are at considerable risk of heat-related illness and injury.  Aged 
humans require a greater increase in Tcore (Tc ≥ 0.9℃ ) to stimulate non-NO dependent 
pathways in comparison to young subjects (Tc ≥ 0.6℃) [5], causing a delay in 
thermoregulatory responses during heat exposure.    
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Reflex Cutaneous Vasodilation and Eccrine Sweating  
Cutaneous vasodilation and eccrine sweating are achieved via sympathetic reflex (whole 
body) and locally mediated pathways.  Central control of thermoregulation is attributed to the 
preoptic/anterior hypothalamus (PO/AH) of the brain.[4]   Sensory input from skin and core 
thermosensors are integrated at the PO/AH which then sends an efferent signal to vascular 
endothelial cells and sweat glands.  Once stimulated, cutaneous vasodilation and sweat 
responses increase proportionately to rising internal temperatures.[2]  Appropriate responses 
from the PO/AH will continue until the internal temperature returns to normal, demonstrating 
a classic homeostatic negative feedback loop.[4]   
It is generally accepted that acetylcholine (ACh) plays a role in mediation of cutaneous 
vasodilation and the eccrine sweat response.  In support of this theory, Kellogg and 
colleagues (9) observed local presynaptic inhibition of cholinergic nerves with botulinum 
toxin completely inhibits both sweating and active cutaneous vasodilation.   
Sweat glands are stimulated by cholinergic nerve terminals in addition to some adrenergic 
terminals. The predominance of ACh in eccrine sweating has been demonstrated via the 
administration of atropine, a muscarinic receptor antagonist which completely abolishes the 
sweat response. Further evidence suggesting a primary role of ACh in sweat production 
includes recent studies which have found that adrenergic receptors do not contribute to the 
sweat response.[6]  
It is hypothesized that vasodilation is induced by the cotransmission ACh and an unknown 
cotransmitter.[9]  This theory is supported by observations that muscarinic blockade with 
atropine slightly delays vasodilation responses during thermal stress.[10]  The partial 
attenuation of SkBf indicates a role of ACh in mediating vasodilation.[10]  As for identification 
of the unknown putative neurotransmitter, vasoactive neuropeptides including vasoactive 
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intestinal peptide (VIP), substance P, and calcitonin gene-related peptide are all purported 
possibilities.[5]  ACh produces vasodilation through various mechanisms including NO-
dependent, prostanoid-dependent, and non-NO-nonprostanoid-dependent pathways.[9]      
NO is a highly reactive free radical that is involved with several physiological pathways, 
including cutaneous vasodilation.  Endothelium-derived NO (ED-NO) is believed to be a 
major active effector of cutaneous vasodilation and generally thought to be required for full 
expression of vasodilation.[9]  In support of this, the inhibition of NO synthase (NOS) reduces 
active vasodilation by approximately 30-40%.[8]  In addition to its role as an effector of 
cutaneous vasodilation, ED-NO serves vascular health in several ways, including: inhibition 
of platelet aggregation, leukocyte adhesion to the endothelial surface and vascular smooth 
muscle proliferation.[11]  ED-NO is synthesized in endothelial cells from the precursor L-
arginine by the enzyme NOS and causes vasodilation by activation of soluble-guanylate 
cyclase-dependent mechanisms to increase cellular cGMP in vascular smooth muscle. [5]  In 
addition to ACh, NO is produced via downstream activation of several putative 
neurotransmitters such as vasoactive intestinal peptide (VIP), substance P, and CGRP.[9] 
In support of this NO-dependent theory, two studies in the late 1990s applied the blockage 
of NOS activity and tested cutaneous vasodilatory responses.  Kellogg et al. (13) used 
intradermal MD to perfuse NOS inhibitor NG-nitro-L-arginine-methyl ester (L-NAME) into the 
skin while another study, Shastry et al.(12) utilized intra-arterial infusions of the NOS 
antagonist L-NNA.  In both studies, cutaneous vasodilation was significantly attenuated, but 
not entirely inhibited, implying NO is a major signaling molecule for cutaneous VD, but there 
are other mechanisms involved.[12, 13]  Wilkins and colleagues (14) examined the role of NO 
as an active effector, rather than a permissive effector via perfusion of SNP (NO donor) with 
L-NAME (NOS antagonist), ensuring a constant supply of NO. They observed an 
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attenuation in active vasodilation during heat stress, regardless of the exogenous NO 
addition.  This indicates that NO mediates vasodilation actively, rather than permissively.[14]   
In addition to NO, evidence suggests a role of prostanoids in active cutaneous vasodilation.  
Like NO, prostaglandins (PGI2) are secreted by endothelial cells in blood vessels and serves 
as a vasodilator.[15]  PGI2 is a metabolic derivative of arachidonic acid (AA) which is 
produced by phospholipase A2 (PLA2) through a Ca+2-dependent step and converted by 
cyclooxygenase (COX).[15]  PGI2 induces vasorelaxation by stimulation of adenylyl cyclase 
and the production of cyclic adenosine monophosphate (cAMP).[15] 
 
Figure 1. Schematic of NO and prostacyclin signaling pathways in regulation of vascular tone. 
Modified from reference [16].  
 
NO is synthesized by NOS from the terminal nitrogen of L-arginine and further acts to 
stimulate vasodilation by soluble-guanylate cyclase-dependent mechanisms to increase 
cellular cGMP.  PGH2 is an AA metabolite formed by cyclooxygenase (COX-1) and 
prostacyclin synthase (PGIS) located in vascular endothelium.  Prostacyclin (PGI2) further 
stimulates adenylate cyclase in vascular smooth muscle cells, increasing cellular cAMP 
which indirectly releases cytosolic calcium and resulting in vasorelaxation.[16]   
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The Relationship between Skin Blood Flow and Eccrine Sweating 
It is logical to consider a functional link between sweating and SkBF since vasodilation 
provides the heat necessary for sweat evaporation as well as the precursor fluid to sweat 
production (blood plasma).  It has additionally been observed that these two mechanisms of 
heat dissipation are often temporally correlated, thus it is suggested that cutaneous 
vasodilation is functionally related to the sweat response.[2] Cutaneous active vasodilation is 
mediated by sympathetic cholinergic active vasodilator nerves and eccrine sweating is 
controlled by sympathetic cholinergic sudomotor nerves.  Whether these nerves comprise a 
single nerve or two separate nerves is still unclear.[2]  
It is generally accepted that ACh is a key molecule in signaling both cutaneous vasodilation 
and the sweat response.[5]  Sweat glands contain both adrenergic and cholinergic receptors, 
yet it appears that cholinergic receptors solely contribute to the sweat response.[6]  It is 
therefore plausible to speculate that a major effector of cutaneous vasodilation and second-
messenger pathway of ACh, NO is also involved in signaling the sweat response.[6]  In 
addition, a study by Welch et al. [17] observed that sweating was lower in skin perfused 
with  NG-nitro-L-arginine methyl ester [ L-NAME, a non-selective NOS inhibitor] through 
intradermal MD, in comparison to during continuous cycling exercise (∼47% of maximum 
oxygen uptake) performed in a hot environment.  It has also been observed that NO 
augments sweat rate during both exogenous acetylcholine administration and active 
exercise heat stress.[10] These results have caused speculations over the potential role of 
NO in signaling sweating.   
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SPECIFIC AIMS  
1.) Develop drug dilutions to elicit cutaneous vasodilation with EPO sodium L-NNA. 
2.) Complete pilot testing to achieve flow matching of cutaneous vasodilatation 
during a whole body heating protocol via  
a. Lactated Ringers  
b. EPO sodium (PGI-II agonist) and L-NNA (NOS inhibitor).   
c. SNP (NO donor) and L-NNA 
3.) To investigate the putative role of NO in eccrine sweat gland signaling in young 
individuals and in primary aging.  
The rationale for the drugs perfused at each of the MD sites is as follows: Lactated Ringers 
is perfused at site A as a control site.  L-NNA is perfused at sites B and C to block NOS and 
therefore endothelial NO production, whilst simultaneously perfusing a drug which 
stimulates cutaneous vasodilation by a specific pathways. This controls the level of 
vasodilation at each of the drug sites and the mechanism causing these responses.  EPO is 
a PGI-2 agonist and serves to mediate cutaneous vasodilation through prostaglandin-
dependent mechanisms while SNP, an NO donor, serves to induce cutaneous vasodilation 
through NO-dependent mechanisms.  By blocking the physiological vasodilation response to 
heat stress (NOS-inhibition) and supplying a drug which elicits vasodilation, this allows for 
comparison of sweating responses associated with each specific pathway. To successfully 
compare sweating responses associated with prostaglandin-dependent mechanisms and 
sweating responses associated with NO-dependent mechanisms, blood flow as a measure 
of cutaneous vascular conductance (CVC) at each site must be matched to the control site, 
requiring experimentation with differing concentrations of L-NNA, SNP, and EPO.  Once this 
step is completed sweating responses between each site may be compared.  It is expected 
that the SNP+L-NNA site and control site will show higher levels of eccrine sweating 
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compared to the EPO+L-NNA site, indicating a role of NO in eccrine sweat gland signaling.  
During flow matching protocol development it was found that EPO does not remain active in 
physiological pH, therefore a buffer was created to maintain drug stability.  Buffer 
development is further explained in Appendix I.    
HYPOTHESIS 
Based on current literature and a putative relation between sweating and SkBF, we 
hypothesize that sweating will be attenuated at the EPO and L-NNA site compared with the 
SNP and L-NNA, and control sites indicating a role for NO in eccrine sweating.   
 
EXPERIMENTAL METHODS  
A series of pilot studies were conducted to develop experimental drug dilutions to achieve a 
successful flow matching protocol.  This required identifying appropriate concentrations of 
vasodilatory drugs combined with a non-specific NO inhibitor to match vasodilation at a 
control site during a whole body warming procedure.   
 
Subjects 
All experimental procedures were approved by the Appalachian State University Institutional 
Review Board and met the ethical guidelines set forth by the declaration of Helinski. Both 
procedures and pharmacological dilutions were approved by the Food and Drug 
Administration (FDA).  Voluntary verbal and written consent were both obtained from 
subjects prior to participation screening.  Two normotensive young women aged 22 and 23 
years of age participated.  All subjects completed a health screen questionnaire prior to 
participation.  Upon arrival at the laboratory, the subjects’ heart rate, blood pressure and 
sublingual temperature were recorded.  Participants provided a urine sample for 
assessment of hydration status via urine specific gravity, and body mass was recorded.   All 
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participants were untrained (neither sedentary nor highly exercise trained, were 
nonsmokers, nondiabetic and were not taking medications including antihypertensives or 
other drugs that may affect the cardiovascular system, including antioxidants, hormone 
replacement therapy, or oral contraceptives.)  Both women were tested in the low hormone 
phase of their menstrual cycle.  
 
Calibration of Laser Doppler Flowmetry 
Laser Doppler probes (model HMT330; Vaisala, Helsinki, Finland) were sequentially placed 
in the calibration fluid, ensuring it was not touching the sides or bottom of the container and 
submerged in the fluid at a 90 degree angle to the bottom of the calibration bottle). During 
the calibration it was ensured that no excessive movement or vibration was within the 
laboratory.  Values were measured with a flux between 200-220 and DC of 80-90.  If values 
were not in the above ranges probes were recalibrated and calibrated prior to every 
experiment.  
 
Calibration of Capacitance Hygrometers 
Prior to experimentation, all equipment provided with the calibration system was were 
washed with alcohol, rinsed with water and then triple rinsed with deionized water 
(conductivity < 0.25µS/cm).  Salts and equipment were handled carefully with gloves to 
ensure salts were not contaminated.   
Capacitance hygrometers were calibrated using Lithium chloride (LiCl) (dry end, offset) and 
Sodium chloride (NaCl) (wet end, gain) as reference points (model HMT330; Vaisala, 
Helsinki, Finland). Each probe was calibrated using LiCl as a reference of 11.3% relative 
humidity (RH) and NaCl as a reference of 75.5% RH.   
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To mix each salt solution, the transit cover of each chamber was opened and pressed on 
the holder. Ion exchanged water was then poured into the chamber; 12 mL of water for LiCl 
and 10 mL of water for NaCl.  The contents of each prepared salt package were then 
poured into each chamber and stirred constantly.  It was ensured that each saturated salt 
solution had the ratio of 60-90% undissolved salt to 10-40% liquid.  It was ensured no more 
than 1 cm of undissolved salt and liquid was at the bottom of each salt chamber.  Each 
chamber was sealed and then left undisturbed for at least 48 hours prior to probe calibration 
to ensure the appropriate humidity was formed inside the chamber above the salt solutions 
in the air.   
For calibration, each T2/RH probe was inserted into a salt chamber containing Lithium 
chloride which creates an 11% RH inside the chamber.  The probe remained in the salt 
chamber for 30 minutes, allowing the sensor to stabilize and the value was recorded.  This 
process was repeated for the NaCl salt solution.  It was ensured that the difference between 
the humidity references was at least 50%.   
 
Additional Calibration 
Prior to each experiment a two-point calibration was performed by inserting , thermocouples 
and thermistors into 25°C and 45°C circulating water baths, respectively and recording the 
voltage in the data acquisition system.   
 
Instrumentation  
Experiments were conducted in a thermoneutral environment.  Following subject check-in, 
MD fibers were inserted into the ventral forearm.   Entry and exit points for MD fiber insertion 
were marked on the skin for three MD sites, avoiding visible blood vessels.  The skin was 
cleaned using sterile technique with betadine and alcohol.  A sterile bag of ice was then 
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placed over the sites for 5 minutes to numb the skin. For each site a 25-gauge needle was 
guided horizontally through the dermis and exited the skin near the exit mark.  Three 
intradermal MD fibers  (25 gauge, MD 2000 Bioanalytical Systems, West Lafayette, IN) were 
inserted into the left ventral forearm and were spaced 4.0 cm apart to prevent cross-
reactivity of pharmacological agents.[9]  The MD probes, consisting a membrane (320 µm 
outer diameter) and connective tubing (650 µm outer diameter), were threaded through the 
lumen of the 25-gauge needle.  The needle was then withdrawn leaving the probe 
membrane in the dermal layer of the skin to deliver pharmacological agents directly to the 
cutaneous vasculature and eccrine sweat glands.   
After MD insertion, lactated Ringer’s solution was perfused at a rate of 2µL/min via 
microinfusion pumps for 60- 90 min to ensure attenuation of the local hyperemic response 
from needle insertion trauma.  Following hyperemia, the subject was instrumented in a water 
perfused suit that covered the entire body except the head, hands, and feet to facilitate 
whole body heating.  Copper-constantan thermocouples were attached at six sites on the 
skin surface to continuously measure skin temperature and an unweighted mean skin 
temperature (Tsk mean) was calculated.  A thermistor was placed in the sublingual sulcus 
throughout baseline and whole body heating to measure oral temperature (Tor) as an index 
of body Tcore.  Appropriate placement was ensured by temperature readings and the 
thermistor was taped in place.  Subjects were instructed to maintain a closed mouth 
throughout baseline and whole body heating to prevent evaporation of moisture from the 
mouth and an inaccurate Tor.  Mean body temperature (Tbody) was calculated as Tbody = (0.9 
× Tor) + (0.1 × mean Tsk).[3]  Laser-Doppler flowmetry probes (MoorLAB; Moor Instruments) 
were placed over each MD site to measure cutaneous red blood cell flux as an index of 
SkBF.  Measurements were continuously recorded during the experiment.  Arterial blood 
pressure was measured via brachial auscultation every 5 minutes following resolution of 
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hyperemia induced by needle insertion trauma.  Mean arterial pressure (MAP) was 
calculated as 1/3 systolic blood pressure + 2/3 diastolic blood pressure.[9]  SkBF was 
expressed as CVC (red blood cell flux/MAP) and normalized as percent of maximal CVC 
values (%CVCmax).[9]  
Pharmacological agents were mounted on the microinfusion pumps throughout the 
experimental protocol.  The delivery of drugs was accomplished through a mixture of 
lactated Ringer’s solution mounted on microinfusion pumps (Bioanalytical Systems Bee hive 
and Baby Bee, West Lafayette, IN) and the desired drugs that reached an isolated area of 
the skin (~2.5 cm2).  A summary table of pharmacological agents and function can be found 
below in Table 1 for further clarification.  Drugs were perfused as follows throughout the 
whole body heating protocol as follows: 
Site 1. Lactated Ringers Solution 
Site 2. EPO & L-NNA   
Site 3. SNP & L-NNA 
 
Drug dilution ranges were 10/50/100/200 ng/mL of EPO mixed with 10mM L-NNA. The SNP 
ranged from 50 µM 100/200/500 µM mixed with 10mM L-NNA.  A summary of the actions of 
each drug are shown in table 1: 
Table 1. Summary of experimental pharmacological agents and their functions. CVC; cutaneous 
vascular conductance.   
Pharmacological 
Agent 
Abbreviation Function  Expected effect on 
CVC 
NG-Nitro-L-arginine L-NNA Non-specific NO 
inhibitor  
Blocks NO-dependent 
vasodilation 
Sodium nitroprusside SNP NO donor Induces vasodilation 
Epoprostenol Sodium EPO Prostacyclin (PGI-2) 
agonist 
Induces vasodilation 
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Local sweating rates were measured using ventilated capsules perfused with compressed 
medical-grade dry nitrogen with a relative humidity of 1-2%.[3] Sweat capsules (0.5 cm2) 
were positioned over the center of each MD fiber. The temperature and humidity of the air 
flowing out of the capsules were measured using capacitance hygrometers that were 
calibrated using reference solutions of known temperature and humidity (model HMT330; 
Vaisala, Helsinki, Finland).[3] Sweating rate (SR) was calculated based on the change in 
relative humidity of the air as it passed through the capsule (Δrh) at a determined air flow 
(AF), the density of saturated steam at the given temperature (D), and the capsules surface 
area (SA), using the following equation:[3] 
SR=[AF×(Δrh/100)×D]/SA. 
 
Experimental Protocol 
Whole body heating 
Following resolution of insertion trauma, baseline data were collected for 20 min ensuring 
mean Tsk was maintained at a thermoneutral temperature using a water-perfused suit 
(34°C).  A thermal comfort scale was verbally asked (1= cold, 5=neutral, 10= hot) at 
baseline and throughout heating. After the collection of baseline, Tsk, Tor, SkBf and SR data, 
50°C water was perfused through the water-perfused suit to elevate Tor by 1°C.  Tor was 
then clamped for 5 min by reducing the temperature of the water perfusion.  After 5 min of 
steady-state laser-Doppler flux values, water perfusing the suit was returned to 34°C and 25 
mM SNP (Nitropress; Abott Laboratories, Chicago, IL) was perfused for 20 min through 
each MD site at a rate of 4 µl/min to obtain maximum SkBF for normalization of CVC values 
to a percentage of maximal SkBF (%CVCmax). 
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MD Drug Perfusion 
Baseline data (BL 1) were collected for 20 min following hyperemia.  After BL 1 
measurements were collected, Tsk was clamped at 34°C (water-perfused suit) during 
perfusion.  Ringer’s solution was perfused as a control site and two sites were perfused with 
a NOS inhibitor, L-NNA for 30 minutes before a second baseline was recorded.  Following 
baseline 2 (BL 2), whole body warming was initiated by perfusing 50 °C water through the 
water-perfused suit.  During heating, SNP and EPO sodium were perfused in combination 
with L-NNA at two separate sites: 
Site 1: Control  
Site 2: SNP + 10 mM L-NNA 
Site 3: EPO sodium + 10 mM L-NNA 
 
The dilutions of SNP and EPO sodium were progressively increased on their respective 
sites to match the vasodilation achieved at the control site. After completion of the perfusion, 
25 mM SNP was perfused through all sites at a rate of 4 µl/min to induce maximal 
cutaneous vasodilation for normalization of data. 
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Figure 1.  A schematic representative of the experimental protocol.  
*Unexpectedly, it was found that EPO is inactive in physiological pH and therefore a buffer was 
created to maintain drug stability throughout the experiment.  Further details may be found in 
Appendix I.   
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RESULTS  
Two pilot studies were conducted to test the drug dilutions of EPO+L-NNA and SNP+L-NNA 
to produce sufficient vasodilation (CVC%max) to match the control site during a whole body 
heating protocol (Figures 1 and 2).  CVC % max values were calculated for each 0.1°C rise 
in Tcore during whole body heating and values were compared across sites.  Figure 1 
illustrates the SkBF responses at the control site versus the EPO+L-NNA and SNP+L-NNA 
sites.   
 
Figure 1. Cutaneous blood flow responses during pilot study 1 expressed as a percentage of 
CVC%max during a whole body heating protocol to a 1°C rise in core temperature (ΔTcore) at three 
sites.  
 
No differences were observed between the maximal values at each site when perfused with 
25mM SNP, which was required for data normalization.  Throughout the whole body heating 
procedure for pilot I, all sites showed a similar pattern of vasodilation, however both the L-
NNA+SNP and L-NNA+EPO sites displayed lower rates of vasodilation than at the control 
site, with L-NNA+SNP demonstrating the lowest values of CVC (%max).  At 0.9°C and 1.0°C 
rise in Tcore the EPO+L-NNA site and control site indicated similar levels of vasodilation.    
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Figure 2. Cutaneous blood flow responses during pilot study 2, expressed as a percentage of 
CVC%max during a whole body heating protocol to a 1°C rise in core temperature (ΔTcore) at three 
sites.  
 
Similar to pilot study 1, no differences were observed between sites for maximal cutaneous 
vasodilation in response to 25mM SNP. Throughout the whole body heating protocol the 
SNP/L-NNA site showed greater vasodilation in compared to the other sites.  At the 1°C rise 
in Tcore, the SNP/L-NNA site showed a value of 88.2 CVC%max versus 53.6 and 22.4 
CVC%max at the Control and EPO+L-NNA sites respectively.   The control site 
demonstrated higher SkBF values compared to the EPO+ L-NNA site throughout the 
protocol. This indicated that EPO was not stimulating PGI-mediated vasodilation as was 
expected, yet the L-NNA was likely blocking NO production.   
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DISCUSSION  
Throughout both pilot studies a whole body heating protocol was successfully utilized to 
elicit cutaneous vasodilation. The magnitude of cutaneous vasodilation at the control sites 
was 53.6% CVC max, similar to that observed in young healthy individuals in other studies 
using a similar protocol.[8]  During pilot study 1, the SNP+ L-NNA and EPO+ L-NNA sites 
both demonstrated lower values of CVC%max compared to the control site, indicating that 
higher concentrations of both drugs were required to flow match the vasodilation with the 
control site.  During the subsequent pilot study (pilot 2), the SNP L-NNA site demonstrated a 
significantly higher rate of CVC%max than the control site, suggesting higher vasodilation 
occurred compared to the control and therefore a greater concentration of SNP was 
administered than necessary.  Unexpectedly, the EPO+ L-NNA site displayed values that 
were lower than the control site, indicating the EPO+ L-NNA solution was ineffective.  After 
analyzing the cutaneous vasodilation data it was evident that the EPO was not effectively 
stimulating PGI-2-mediated vasodilation as had been anticipated. Considering the SkBF 
was lower than the control site during pilot study 2, this indicates that the L-NNA was 
effectively blocking NO-dependent vasodilation, but PGI-2 mediated vasodilation not was 
occurring, thus resulting in low blood flow.  After further investigation, despite the EPO being 
soluble in Lactated Ringer’s (physiological pH), the pharmacological company supplying the 
drug could not confirm it would remain stable. The half-life of EPO is reported to be short in 
vivo and in vitro reported to range from 30 seconds to a few minutes at a physiological pH, 
making it difficult to mix and administer successfully in Lactated Ringer’s. To remain active 
EPO sodium requires a pH of 10.4 and therefore must be dissolved in a buffer. A suitable 
buffer was developed involving a mixture of sodium bicarbonate and sodium carbonate to 
achieve a pH of 10.48. The solution was then mixed with (HCl) to return the buffer to 
physiological pH OF 6.74.   
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The next step in this study includes ensuring that the EPO does not precipitate out of the 
buffer as it is brought back to a physiological pH with HCl.  Additional pilot studies would 
then be completed to ensure EPO remains active when dissolved in the buffer, brought back 
to physiological pH with HCl and administered via MD (dose response pilot.)  Pilot studies 
for whole body heating to match blood flow at each site would then be conducted, including 
a control site, an EPO+ L-NNA site and an SNP+ L-NNA site.  Once flow matching has been 
achieved between sites, the sweating study in which the whole body heating protocol is 
utilized with the addition of the sweat system to measure regional sweat rates over each MD 
site may begin.  It is expected that sweating responses will be lower at the EPO+L-NNA site 
versus the SNP+L-NNA site, indicating a role for NO in signaling the eccrine sweat 
response.  If sweat rates do not significantly differ evidence will not support a role for neither 
prostaglandin-dependent nor NO-dependent vasodilation mechanisms in additionally 
signaling the sweat response.   
It has been consistently observed that the aged population experience attenuated 
cutaneous vasodilation and sweat responses as well as increasingly rely on blunted NO-
dependent mechanisms to achieve cutaneous vasodilation.  Considering these age-related 
decrements associated with NO, it is likely that sweat rate will be observed as lower with 
aging resulting in a reduction in NO-signaling for the sweat response.   
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APPENDIX I 
 
 
Buffer Development 
Following analysis of data from pilot study 2, it was observed that the EPO sodium was 
inactive when administered via MD (see discussion for further details).  It was established 
that EPO sodium becomes inactive in solutions with a pH lower than 10.4.  Considering 
physiological pH is approximately 7.4, EPO sodium will not remain active when dissolved 
and administered under these conditions.  To ensure maintenance of an active form of EPO 
during experimentation, a buffer was created at room temperature to provide a stock 
solution.  The following procedures were utilized to develop an appropriate buffer:  
A two-point calibration was performed before each use of the pH probe with two solutions of 
a known pH (pH 7, pH 10). The probe was thoroughly rinsed with ultrapure water prior to 
and between calibrations.  Following calibration, separate formulas of either sodium 
bicarbonate or sodium carbonate dissolved in ultrapure water were mixed to determine their 
pH. Table 1 shows the pH achieved utilizing these separate mixtures, neither of which were 
of a suitable pH for use with EPO sodium.  
 
Table 1. Details of initial buffer development utilizing sodium bicarbonate and sodium carbonate.   
Chemical Compound g/100 mL ultrapure water pH 
Sodium bicarbonate 
(NaHCO3) 
0.851  8.27 
Sodium carbonate (Na2CO3) 2.831 11.48 
 
To achieve the desired pH of ~10.4, a combination of sodium bicarbonate and sodium 
carbonate was required.  
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Table 2.  Details of buffer development utilizing a combined mixture of sodium bicarbonate and 
sodium carbonate. 
Solution Volume of Sodium bicarbonate 
(NaHCO3) solution of 8.27 pH 
(ml) 
Volume of Sodium 
carbonate (Na2CO3) 
solution of 11.48 pH 
(ml) 
pH 
1 15 35 10.70 
2 20 35 10.57 
3 25 35 10.48 
4 30 35 10.41 
 
The next step required returning the buffer to a physiological pH. Lactated Ringer’s was 
added to the sodium bicarbonate/sodium carbonate buffer mixture (pH 10.41). As shown in 
Table 3, Lactated Ringer’s was unable to bring the buffer to a pH lower than 10.19.  
 
Table 3. Dilutions of the sodium bicarbonate/sodium carbonate buffer with Lactated Ringer’s. 
Solution Volume of Sodium 
bicarbonate/sodium carbonate 
buffer solution of 10.41 pH (ml) 
Volume of Lactated 
Ringer’s (ml) 
Final pH 
1 3 3 10.45 
2 1 9 10.36 
3 0.1 9.9 10.19 
 
 Due to the inability of Lactated Ringer’s to sufficiently reduce the pH of the buffer solution, 1 
molar (1M) hydrochloric acid (HCl) was utilized. A suitable pH for administration of the EPO 
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sodium via MD was achieved, as show in from the dilutions of the buffer solution to the 
HCl(1M) in Table 4.   
Table 4. Dilutions of the sodium bicarbonate/sodium carbonate buffer with (HCl).  
Solution Volume of Sodium 
bicarbonate/sodium carbonate 
buffer  solution of 10.41 pH 
(ml) 
Volume of 1M HCl 
(ml) 
Final pH 
1 9 0.5 9.38 
2 9 1.0 6.74 
 
 
